ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1402

Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry

Xiuying Li1, Angela Cesta1, Mohammad Movahedi2 and Claire Bombardier3, 1University Health Network, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Demographics, Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a sub-group of patients traditionally defined as onset of RA after the age of 60 years. Compared to younger onset rheumatoid arthritis (YORA) which occurs before the age of 60 years, LORA has unique characteristics and disease manifestations. The prognosis of LORA patients is less clear based on prior studies. We compared the clinical characteristics, time to remission and treatment regimen at remission between LORA and YORA patients.

Methods: The Ontario Best Practices Research Initiative (OBRI) is a clinical registry of RA patients followed in routine care. This analysis used the OBRI database from 2008 to 2020. Patients were included if they had active RA disease (≥1 swollen joint) and were enrolled in the study within 1 year of diagnosis. LORA was defined as diagnosis of RA after age of 60, YORA as under age of 60. Remission was defined by Disease Activity Score 28 (DAS28) ≤2.6. A multivariable Cox proportional hazards model was used to estimate time to remission.

Results: The study included 354 LORA patients and 518 YORA patients. Compared to YORA patients, LORA patients were less likely to be female (66% vs. 80% p< 0.0001), and less likely to have positive either rheumatoid factor or anti-cyclic citrulinated peptide antibody (63% vs. 75% p=0.0003). The mean (standard deviation) baseline DAS28 score was 5.0 (1.3) and 4.8 (1.2) in LORA and YORA patients, respectively (p=0.0946). During the study follow-up, 254 (72%) LORA and 405 (78%) YORA patients reached remission (Figure). Compared to YORA patients, the hazard ratio (HR) for remission in LORA patients was 1.10 (95% confidence interval 0.90 to 1.34 p=0.35) after adjusting for other prognostic factors (table). For patients who reached remission, LORA patients were less likely to be on a biologic or JAK inhibitor (16% vs. 27%) and more likely to be on a single conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) (34% vs. 27%) compared to YORA patients (chi-square test for all drug groups p=0.0039).

Conclusion: LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor. Clinicians should take the same approach for all RA patients targeting remission regardless of age of onset.

Reference:
Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clinical rheumatology. 2016 Mar;35(3):759-63.

Supporting image 1

*HAQ-DI = health assessment questionnaire disability index

Supporting image 2


Disclosures: X. Li, None; A. Cesta, None; M. Movahedi, None; C. Bombardier, Amgen, AbbVie, Gilead, Janssen, Eli Lilly, Merck/MSD, Medexus, Medreleaf/Aurora, Novartis, Pfizer, Roche, Sandoz, Sanofi/Genzyme, Samsung, Mylan, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Li X, Cesta A, Movahedi M, Bombardier C. Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/late-onset-rheumatoid-arthritis-has-a-similar-remission-rate-as-younger-onset-rheumatoid-arthritis-results-from-an-ontario-rheumatoid-arthritis-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/late-onset-rheumatoid-arthritis-has-a-similar-remission-rate-as-younger-onset-rheumatoid-arthritis-results-from-an-ontario-rheumatoid-arthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology